WSGR logoWSGR logo
WSGR logo
  • Experience
  • People
  • Insights
  • About Us
  • Careers

  • Practice Areas
  • Industries

  • Corporate
  • Intellectual Property
  • Litigation
  • Patents and Innovations
  • Regulatory
  • Technology Transactions

  • Capital Markets
  • Corporate Governance
  • Corporate Life Sciences
  • Derivatives
  • Emerging Companies and Venture Capital
  • Employee Benefits and Compensation
  • Energy and Climate Solutions
  • Executive Advisory Program
  • Finance and Structured Finance
  • Fund Formation
  • Greater China
  • Mergers & Acquisitions
  • Private Equity
  • Public Company Representation
  • Real Estate
  • Restructuring
  • Shareholder Engagement and Activism
  • Tax
  • U.S. Expansion
  • Wealthtech

  • Special Purpose Acquisition Companies (SPACs)

  • Environmental, Social, and Governance

  • AI and Data Center Infrastructure
  • Energy Regulation and Competition
  • Project Development and M&A
  • Project Finance and Tax Credit Transactions
  • Sustainability and Decarbonization
  • Transportation Electrification

  • U.S. Expansion Library and Resources

  • Post-Grant Review
  • Trademark and Advertising

  • Antitrust Litigation
  • Arbitration
  • Board and Internal Investigations
  • Class Action Litigation
  • Commercial Litigation
  • Consumer Litigation
  • Corporate Governance Litigation
  • Employment Litigation
  • Executive Branch Updates
  • Government Investigations
  • Internet Strategy and Litigation
  • Patent Litigation
  • Securities Litigation
  • State Attorneys General
  • Supreme Court and Appellate Practice
  • Trade Secret Litigation
  • Trademark and Copyright Litigation
  • Trial
  • White Collar Crime

  • Advertising, Promotions, and Marketing
  • Antitrust and Competition
  • Committee on Foreign Investment in the U.S. (CFIUS)
  • Communications
  • Data, Privacy, and Cybersecurity
  • Export Control and Sanctions
  • FCPA and Anti-Corruption
  • FDA Regulatory, Healthcare, and Consumer Products
  • Federal Trade Commission
  • Fintech and Financial Services
  • Government Contracts
  • National Security and Trade
  • Payments
  • State Attorneys General
  • Strategic Risk and Crisis Management
  • Tariffs, Customs, and Import Compliance

  • Antitrust and Intellectual Property
  • Antitrust Civil Enforcement
  • Antitrust Compliance and Business Strategy
  • Antitrust Criminal Enforcement
  • Antitrust Litigation
  • Antitrust Merger Clearance
  • European Competition Law
  • Third-Party Merger and Non-Merger Antitrust Representation

  • Anti-Money Laundering
  • Foreign Ownership, Control, or Influence (FOCI)
  • Team Telecom

  • AI in Healthcare
  • Animal Health
  • Artificial Intelligence and Machine Learning
  • Aviation
  • Biotech
  • Blockchain and Cryptocurrency
  • Clean Energy
  • Climate and Clean Technologies
  • Communications and Networking
  • Consumer Products and Services
  • Data Storage and Cloud
  • Defense Tech
  • Diagnostics, Life Science Tools, and Deep Tech
  • Digital Health
  • Digital Media and Entertainment
  • Electronic Gaming
  • Fintech and Financial Services
  • FoodTech and AgTech
  • Global Generics
  • Internet
  • Life Sciences
  • Medical Devices
  • Mobile Devices
  • Mobility
  • NewSpace
  • Quantum Computing
  • Semiconductors
  • Software

  • Offices
  • Country Desks
  • Events
  • Community
  • Our Diversity
  • Sustainability
  • Our Values
  • Board of Directors
  • Management Team

  • Austin
  • Boston
  • Boulder
  • Brussels
  • Century City
  • Hong Kong
  • London
  • Los Angeles
  • New York
  • Palo Alto
  • Salt Lake City
  • San Diego
  • San Francisco
  • Seattle
  • Shanghai
  • Washington, D.C.
  • Wilmington, DE

  • Law Students
  • Judicial Clerks
  • Experienced Attorneys
  • Patent Agents
  • Business Professionals
  • Alternative Legal Careers
  • Contact Recruiting
Michael Brito-Stamm
Associate
Corporate
Century City
mbritostamm@wsgr.com

D424-446-6915

Download vCard
Open PDF
  • Comprehensive Corporate Experience

    Michael advises public and private pharmaceutical, life science, and technology companies in a broad range of matters, including capital markets transactions, Securities Exchange Act reporting, corporate governance, licensing and collaboration transactions and other strategic transactions. Michael works closely with directors and senior management on a wide variety of legal issues, including executive employment and compensation, fiduciary duties, compliance issues and organizational matters.

Michael Brito-Stamm is an associate in the Century City office of Wilson Sonsini Goodrich & Rosati, where he focuses his capital markets practice on debt and equity securities offerings, including IPOs and follow-on offerings, and public and private mergers and acquisitions. He regularly advises his clients on capital structuring and raising, corporate governance, securities regulation, and compliance issues.

Michael’s practice also includes counseling companies, from start-ups to well-seasoned issuers, on corporate governance, ongoing SEC compliance, and other general corporate matters. He advises clients on compliance with the Securities Act of 1933, Securities Exchange Act of 1934, and the rules and regulations of the Securities and Exchange Commission and Financial Industry Regulatory Authority. He works closely with directors and senior management on a broad range of other legal matters, including fiduciary duties, compliance issues, and organizational matters.

Prior to joining the firm, Michael was an associate at Troutman Pepper Hamilton Sanders in New York.

Experience

Michael Brito-Stamm is an associate in the Century City office of Wilson Sonsini Goodrich & Rosati, where he focuses his capital markets practice on debt and equity securities offerings, including IPOs and follow-on offerings, and public and private mergers and acquisitions. He regularly advises his clients on capital structuring and raising, corporate governance, securities regulation, and compliance issues.

Michael’s practice also includes counseling companies, from start-ups to well-seasoned issuers, on corporate governance, ongoing SEC compliance, and other general corporate matters. He advises clients on compliance with the Securities Act of 1933, Securities Exchange Act of 1934, and the rules and regulations of the Securities and Exchange Commission and Financial Industry Regulatory Authority. He works closely with directors and senior management on a broad range of other legal matters, including fiduciary duties, compliance issues, and organizational matters.

Prior to joining the firm, Michael was an associate at Troutman Pepper Hamilton Sanders in New York.

Education
  • J.D., University of Virginia School of Law, 2014

    Editor, Virginia Law & Business Review

  • B.S., Neuropsychology, Tufts University, 2009
Admissions
  • State Bar of California
  • State Bar of New York
Credentials
Education
  • J.D., University of Virginia School of Law, 2014

    Editor, Virginia Law & Business Review

  • B.S., Neuropsychology, Tufts University, 2009
Admissions
  • State Bar of California
  • State Bar of New York
Focus Areas
  • Capital Markets
  • Corporate
  • Corporate Governance
  • Emerging Companies and Venture Capital
  • Mergers & Acquisitions
Recent Insights
Client Highlights
Wilson Sonsini Advises ImmunityBio on Execution of $80 Million Equity Financing
On July 25, 2025, ImmunityBio, a biotechnology company developing therapies that bolster the natural immune system to defeat cancers and infectious diseases, announced it has executed financing to provide further working capital and support its ongoing business operations. The company entered into a securities purchase agreement for a registered direct offering with two institutional investors, providing for the issuance of common stock of ImmunityBio as well as warrants for the purchase of additional shares of common stock of ImmunityBio that is expected to result in gross proceeds at closing of approximately $80 million before deducting placement agent fees and other offering-related expenses, subject to customary closing conditions. If fully exercised, the warrants could result in additional gross proceeds of up to approximately $96 million. Wilson Sonsini Goodrich & Rosati advised ImmunityBio on the transaction.
 
The Wilson Sonsini team advising ImmunityBio includes:
 
Corporate 
Marty Waters
Ben Capps
David Sharon
Michael Brito-Stamm
Brandon Shaw
James Keegan
 
Patents and Innovations
Matt Bresnahan
Matt Wheeler
Yingchun Ni
 
For more information, please see ImmunityBio’s press release.
Learn More
Client Highlights
Wilson Sonsini Advises Aadi Bioscience on $100 Million Sale of FYARRO®, $100 Million PIPE Financing and License Agreement for ADC Portfolio
On December 19, 2024, Aadi Bioscience announced that it had entered into an agreement to sell its commercial drug product FYARRO® to KAKEN Pharmaceutical for $100 million, an agreement to sell and issue $100 million of equity in a PIPE financing, and an exclusive license agreement for the development and global commercialization of a three-asset portfolio of preclinical, next-wave antibody-drug conjugates (ADCs), in collaboration with WuXi Biologics, a global Contract Research, Development and Manufacturing Organization, and Hangzhou DAC, a global leader in ADC innovation.
Learn More
View All
  • people
  • insights
  • about us
  • careers
  • Binder
  • Alumni
  • Mailing List Signup
  • Client FTP Portal
  • Privacy Policy
  • Terms of Use
  • Accessibility
WSGR logo
Twitter
LinkedIn
Facebook
Instagram
Youtube
Copyright © 2026 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.